Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Margit Spatzenegger"'
Publikováno v:
Pharmacology & Toxicology. 86:71-77
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be03b59dd155ae466b661db408b6dff8
https://doi.org/10.1034/j.1600-0773.2000.pto860205.x
https://doi.org/10.1034/j.1600-0773.2000.pto860205.x
Autor:
Walter Jaeger, Michaela Miksits, Theresia Thalhammer, Margit Spatzenegger, Marek Murias, Thomas Szekeres, Sylvia Aust
Publikováno v:
Cancer Letters. 261:172-182
Resveratrol is a polyphenolic compound present in grapes and wine with anticancer activities that undergoes pronounced metabolism in humans. In order to determine whether metabolism of resveratrol also occurs in tumor cells and whether biotransformat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7330f3ef101001568f93c04866dcda69
https://doi.org/10.1016/j.canlet.2007.11.008
https://doi.org/10.1016/j.canlet.2007.11.008
Autor:
Andrea E. DeBarber, Dennis R. Koop, Hong Liu, Margit Spatzenegger, Qinmi Wang, James R. Halpert
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 304:477-487
Human CYP2B6 and CYP2E1 were used to investigate the extent to which differential substrate selectivities between cytochrome P450 subfamilies reflect differences in active-site residues as opposed to distinct arrangement of the backbone of the enzyme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec075f360ad4281455566666fa06a515
https://doi.org/10.1124/jpet.102.043323
https://doi.org/10.1124/jpet.102.043323
Publikováno v:
Pharmacology & Toxicology. 86:242-244
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2925bfec9e163fcc336706f56c209f4
https://doi.org/10.1034/j.1600-0773.2000.pto860508.x
https://doi.org/10.1034/j.1600-0773.2000.pto860508.x
Publikováno v:
Drug Metabolizing Enzymes ISBN: 9780824742935
Drug Metabolizing Enzymes
Drug Metabolizing Enzymes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74bea9b1299c9900e5af002c933e1978
https://doi.org/10.1201/9781420028485.ch6
https://doi.org/10.1201/9781420028485.ch6
Publikováno v:
Archives of biochemistry and biophysics. 395(1)
The hydrophobic membrane-spanning domain in four cytochromes P450 2B was removed (Delta3-21) and several positive charges were substituted at the N-terminus to increase expression and solubility. Histidine residues were appended to the C-terminus to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c8d8b2dbbffcc87e4187eacb3b413b
https://pubmed.ncbi.nlm.nih.gov/11673866
https://pubmed.ncbi.nlm.nih.gov/11673866
Autor:
Qinmi Wang, James R. Halpert, You Qun He, Eric F. Johnson, Margit Spatzenegger, Michael R. Wester
Publikováno v:
Molecular pharmacology. 59(3)
The molecular basis for reversible inhibition of rabbit CYP2B4 and CYP2B5 and rat CYP2B1 by phenylimidazoles was assessed with active-site mutants and new three-dimensional models based on the crystal structure of CYP2C5. 4-Phenylimidazole was 17- to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e1172299dbb2a7efc9f9a09c9cdc61
https://pubmed.ncbi.nlm.nih.gov/11179442
https://pubmed.ncbi.nlm.nih.gov/11179442
Publikováno v:
Pharmacologytoxicology. 86(2)
Differences in expression of CYP1A isoforms (CYP1A1 and CYP1A2) in liver and small intestine of male Wistar rats and their inducibility by 3-methylcholanthrene as well as the effect of different CYP1A1/1A2 expression on caffeine metabolism were inves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09d2501b06a357a6eac42e75022fab69
https://pubmed.ncbi.nlm.nih.gov/10728918
https://pubmed.ncbi.nlm.nih.gov/10728918
Publikováno v:
Biomedical chromatography : BMC. 10(3)
A specific and sensitive method for the determination of PFP 6, a new compound for reverting multidrug resistance, and its two main metabolites in human liver microsomes has been developed. Samples were almost quantitatively isolated by solid phase e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5db41cdc5a37d2091382f7b641bb95
https://pubmed.ncbi.nlm.nih.gov/8792863
https://pubmed.ncbi.nlm.nih.gov/8792863
Autor:
Martin J. Wolfsegger, Reinhard Stidl, Barbara Dietrich, Eva-Maria Muchitsch, Hartmut J. Ehrlich, Hans Peter Schwarz, Friedrich Scheiflinger, Margit Spatzenegger
Publikováno v:
Blood. 118:4345-4345
Abstract 4345 Baxter and Nektar have developed BAX 855, a PEGylated form of Baxter’s recombinant FVIII (rFVIII) product based on the ADVATE™ manufacturing process. The objective of this preclinical study program was to evaluate the safety of BAX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e29992f17f971bcc9fb363ca348baa8a
https://doi.org/10.1182/blood.v118.21.4345.4345
https://doi.org/10.1182/blood.v118.21.4345.4345